



J004 Res'd PCT/PTO 17 OCT 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 47

Application Number	10/545,193
Filing Date	August 10, 2005
First Named Inventor	Gendreau
Art Unit	
Examiner Name	
Attorney Docket Number	EX04-013C-US

ENCLOSURES (check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Copies of references
Return Receipt Postcard |
|--|--|--|

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm

EXELXIS, INC.

Signature

Printed Name

Laleh Shayesteh

Date

October 13, 2005

Reg.
No.

47,937

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name


Laleh Shayesteh

Date

October 13, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Gendreau *et al.*

Application No.: 10/545,193

Filed: August 10, 2005

For: DYRKS AS MODIFIERS OF THE
APC AND AXIN PATHWAYS AND
METHODS OF USE

Confirmation No.: 2158

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX04-013C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with 37 C.F.R. §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R. §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: October 13, 2005


Laleh Shayesteh
Tel: (650) 837-8223; Fax: (650) 837-8234

Reg. No. 47,937



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of Gendreau *et al.*

Application No.: 10/545,193

Filed: August 10, 2005

For: DYRKS AS MODIFIERS OF THE
APC AND AXIN PATHWAYS AND
METHODS OF USE

Confirmation No.: 2158

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX04-013C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO200006728, INCYTE PHARMACEUTICALS, INC., 2000-02-10
US5972606, SmithKline Beecham Corporation, 1999-10-26
US6159716, SmithKline Beecham Corporation, 2000-12-12
WO200073469, SUGEN, INC., 2000-12-07
WO2003031650, BAYER AKTIENGESellschaft, 2003-04-17
US6323318, SmithKline Beecham Corporation, 2001-11-27
US6001623, SmithKline Beecham Corporation, 1999-12-14
US6365389, SmithKline Beecham Corporation, 2002-04-02

The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: October 13, 2005


Laleh Shayesteh
Tel: (650) 837-8223; Fax: (650) 837-8234

Reg. No. 47,937



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/545,193
Filing Date	8.10.2005
First Named Inventor	Gendreau
Art Unit	
Examiner Name	
Attorney Docket Number	EX04-013C-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Wang,X., et al. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2), transcript variant 1, mRNA. GI:5922002 23-SEP-2005	
	2	Wang,X., et al. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2), transcript variant 2, mRNA. GI:5922003 23-SEP-2005	
	3	Li,K., et al. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 (DYRK3), mRNA. GI:4503428 23-AUG-2004	
	4	Becker,W., et al. Homo sapiens mRNA for protein kinase, Dyrk3. GI:8218089 18-APR-2005	
	5	Lord,K.A., et al. Homo sapiens regulatory erythroid kinase long form (RED) mRNA, alternatively spliced product, complete cds. GI:10441414 25-OCT-2002	
	6	Strausberg,R.L., et al Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3, transcript variant 2, mRNA (cDNA clone MGC:9059 IMAGE:3913541), complete cds. GI:15930120 07-SEP-2004	
	7	Strausberg,R.L., et al Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3, mRNA (cDNA clone IMAGE:4822647), complete cds. GI:22713387 28-JUL-2005	
	8	International Human Genome Sequencing Consortium. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 (DYRK4), mRNA. GI:20550208 05-JAN-2003	
	9	Becker,W. et al. H.sapiens mRNA for protein kinase, Dyrk4, partial. GI:1669684 18-APR-2005	
	10	Strausberg,R.L., et al. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4, mRNA (cDNA clone MGC:39640 IMAGE:5266287), complete cds. GI:21411487 28-JUL-2005	
	11	Lorenz,B., et al. Homo sapiens protein-kinase DYRK4 (DYRK4) mRNA, partial cds. GI:9652079 02-AUG-2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number 10/545,193

Filing Date 8.10.2005

First Named Inventor Gendreau

Art Unit

Examiner Name

Attorney Docket Number EX04-013C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Zhang,D., et al. Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 (DYRK4), mRNA. GI:28827773 23-SEP-2005	
	13	Wang,X., et al. dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 1 [Homo sapiens]. GI:4503427 23-SEP-2005	
	14	Wang,X., et al. dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 2 [Homo sapiens]. GI:5922004 23-SEP-2005	
	15	Li,K., et al. dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 [Homo sapiens]. GI:4503429 23-AUG-2004	
	16	International Human Genome Sequencing Consortium. similar to Dual-specificity tyrosine-phosphorylation regulated kinase 4 [Homo sapiens]. GI:20550209 05-JAN-2003	
	17	Zhang,D., et al. dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 [Homo sapiens]. GI:28827774 23-SEP-2005	
	18	Miller C.T. et al. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res. 2003 Jul 15;63(14):4136-43.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.